Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$73.17 USD

73.17
8,786,290

-0.09 (-0.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 4.17% and 1.77%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

NextGen (NXGN) Q2 Earnings Top Estimates, Margins Down

NextGen's (NXGN) second-quarter fiscal 2024 results reflect strength in its Recurring revenues.

Urmimala Biswas headshot

Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More

Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.

Shockwave Medical (SWAV) Announces IVL Studies' Positive Results

Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.

The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific

Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Visa, AbbVie & BHP

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and BHP Group Limited (BHP).

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down

Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Here is how Boston Scientific (BSX) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Recovery

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise

Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.

Here's Why You Should Invest in Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.

PBH or BSX: Which Is the Better Value Stock Right Now?

PBH vs. BSX: Which Stock Is the Better Value Option?

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management

Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.

Boston Scientific (BSX) Set to Acquire Relievant Medsystems

Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.

Sheraz Mian headshot

Top Stock Reports for Amazon.com, Boeing, Regeneron & Others

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).

PBH vs. BSX: Which Stock Is the Better Value Option?

PBH vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval

Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.

Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.